PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
8.7K / 3.59M (Avg.)
-1.55 | -0.04
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
13.84%
Net income growth under 50% of CRN.AX's 47.33%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
71.91%
Some D&A expansion while CRN.AX is negative at -26.77%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-147.63%
Negative yoy while CRN.AX is 384.41%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-46.46%
Negative yoy CFO while CRN.AX is 16496.02%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-113.23%
Negative yoy CapEx while CRN.AX is 58.16%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We reduce yoy sales while CRN.AX is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-194.24%
Both yoy lines negative, with CRN.AX at -37.14%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-551.86%
We reduce yoy invests while CRN.AX stands at 67.40%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy issuance while CRN.AX is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
100.00%
Buyback growth of 100.00% while CRN.AX is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.